November 20, 2025
OXFORD, UK and CLEVELAND, Ohio, US, 20 November 2025 – The Oxford-Harrington Rare Disease Centre (‘OHC’) today announced the recipients of the 2025 Rare Disease Scholar Award, which advances promising discoveries from academic labs into clinical practice. Each Scholar will receive an advisory team providing...
Continue ReadingJune 06, 2016
When the Lauder family founded the Alzheimer’s Drug Discovery Foundation (ADDF) in 1998, they knew that proprietary boundaries would only limit efforts to develop effective Alzheimer’s drugs. So they resolved to make the ADDF’s knowledge available to everyone working to overcome this devastating disease—and all the... Continue Reading
May 05, 2016
For the past decade, venture philanthropists have been working to propel promising therapies and vaccines into the clinic, with some success.Venture philanthropist Bill Gates looks on as a health worker vaccinates a child in GhanaIn December 2015, Facebook founder Mark Zuckerberg and his wife Priscilla Chan made a stunning... Continue Reading
May 02, 2016
CLEVELAND AND INDIANAPOLIS – May 2, 2016 – BioMotiv, a drug development accelerator associated with the Harrington Project, and Indiana University Research and Technology Corp. announce the formation of a new biotechnology start-up, Allinaire Therapeutics. Allinaire Therapeutics aims to develop novel therapeutics for... Continue Reading
May 01, 2016
- 2016 Gund-Harrington Scholar Continue Reading
May 01, 2016
- 2016 Oxford-Harrington Scholar Continue Reading
April 18, 2016
LONDON, APRIL 18, 2016: - Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organization... Continue Reading
April 13, 2016
WILMINGTON, MA, April 13, 2016 – Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into a strategic partnership with BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development. Through this partnership, Charles River will... Continue Reading
March 15, 2016
2016 Harrington Prize for Innovation in Medicines Recognizes Discovery of Leptin and the Leptin-Mediated Pathway Continue Reading
February 29, 2016
Formed by BioMotiv and Rutgers UniversityCLEVELAND AND NEW BRUNSWICK— FEBRUARY 29, 2016— BioMotiv, a drug development accelerator associated with The Harrington Project, and Rutgers, the State University of New Jersey, are announcing the formation of a new biotechnology startup, Z53 Therapeutics. Z53 Therapeutics aims to... Continue Reading
February 11, 2016
Dr. Jonathan Stamler, director of The Harrington Discovery Institute at University Hospitals in Cleveland, has earned a reputation as a “genius.”“Some people are geniuses,” his fatherâinâlaw Norman Wain said. “Geniuses have a capacity to work.”“He has this sort of infectious personality to want to drive... Continue Reading